Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.53 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$151.53M
Enterprise Value$74.01M
Total Cash (Recent Filing)$80.89M
Total Debt (Recent Filing)$10.12M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue328.93
Enterprise Value/Gross Profit227.02
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$10.33Price Target Upside676.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$10.21M
Bulls Say, Bears Say
Bulls Say
Strategic Collaboration With AlnylamThe Alnylam collaboration brings near-to-medium-term non-dilutive funding (up to $10M upfront, milestones up to $1.13B) and partner validation. Structurally this can de-risk programs, fund development milestones, and accelerate clinical timelines without immediate equity dilution.
Low Leverage And Positive EquityTenaya's low debt-to-equity (~0.10) and positive equity (~$106.2M) provide balance-sheet flexibility to raise debt or partner non-dilutive financing if needed. This structural financial cushion supports continued R&D investment and negotiating power with collaborators over the next several quarters.
Specialized Cardiovascular Gene/cell Therapy PipelineA focused pipeline in gene and cell therapies for heart disease builds a durable competitive position: high scientific barriers, specialized expertise, and strong partner interest. This strategic focus increases the chance of differentiated assets that can attract long-term partnerships or premium commercialization pathways.
Bears Say
High Cash BurnPersistent negative operating and free cash flow (~-$64M TTM) indicates material runway pressure and a structural reliance on external financing. Over 2-6 months this elevates the probability of financing events, which can be dilutive or restrict strategic optionality if clinical progress stalls.
Minimal Revenue, Deep Operating LossesWith virtually no product revenue (~$0.2M TTM) and a large net loss (~-$83M), the firm lacks an internally generated, durable revenue base. This structural weakness means long-term viability depends on successful clinical outcomes or sustained external funding rather than operating cash generation.
Dilution Risk From Expanded Equity PlanThe one-time 6.5M share increase (~3% of outstanding) and relaxed evergreen provision materially raise potential equity issuance capacity. Combined with ongoing cash burn and shrinking equity/assets, this creates a durable dilution pathway that can erode per-share economics if additional funding is required.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.53 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $151.53M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.002.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,998,870 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went up 7.342%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (676.94% Upside)
$10.33 (676.94% Upside)
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-80.56%
Trailing 12-Months
Asset Growth
-6.17%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc. is a U.S.-based biotechnology firm focused on unearthing, advancing, and providing novel treatments for various cardiovascular diseases. The company harnesses advanced scientific platforms, including cellular regeneration, gene therapy, and precision medicine, to develop its therapeutic candidates. Among its primary therapeutic initiatives is TN-201, an adeno-associated virus (AAV)-based gene therapy engineered to tackle genetic hypertrophic cardiomyopathy (gHCM) arising from haploinsufficient mutations in the myosin binding protein C3 (MYBPC3) gene. A prominent compound in its pipeline is TN-301, a small molecule histone deacetylase 6 inhibitor (HDAC6i) slated for use in both heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Tenaya is also progressing TN-401, another AAV-based gene therapy aimed at genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) resulting from specific plakophilin 2 (PKP2) gene anomalies. Further, an AAV gene therapy is under development that seeks to introduce the dwarf open reading frame (DWORF) gene into cardiac tissue to address dilated cardiomyopathy (DCM). Rounding out its innovative portfolio, the 'Reprogramming program' employs an AAV-driven approach for cardiac regeneration, striving to replenish heart cells lost in patients who experience heart failure subsequent to a prior myocardial infarction. Founded in 2016, Tenaya operates from its base in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$10.33
▲(676.94% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
23.34% Insiders
4.58% Mutual Funds
7.28% Other Institutional Investors
60.24% Public Companies and Individual Investors